PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
12535855-8	2003	The rank order of beta(1)-adrenoceptor selectivity (K(i)(beta(2))/K(i)(beta(1)) ratio) was nebivolol (for [3H]CGP 12.177 46.1 and for [125I]iodocyanopindolol 22.5)>bisoprolol (13.1 and 6.4)>carvedilol (0.65 and 0.41).	Iodocyanopindolol	140-157	adrenoceptor beta 1	Homo sapiens	18-38
19098126-5	2009	Density of beta(2)-AR assessed by (-)-[(125)I]iodocyanopindolol binding was decreased in hypoxia (-22%).	Iodocyanopindolol	46-63	adrenoceptor beta 2	Rattus norvegicus	11-21
17418176-6	2007	The solubilised beta(2)-adrenergic receptor retained its binding affinity in a radio-receptor assay based on the competition for the binding to receptors between a ligand (beta-agonist or antagonist) and the radioligand [(125)I]iodocyanopindolol.	Iodocyanopindolol	228-245	adrenoceptor beta 2	Homo sapiens	16-43
12878144-6	2003	Competition studies using the non-selective AR ligand, [(125)I]iodocyanopindolol ([(125)I]ICYP), and ventricular membrane preparations of wild-type mice revealed nine ligands with higher beta(1)-AR affinities (up to 76-fold) and beta(1)-AR selectivities (up to 139-fold) than 8i.	Iodocyanopindolol	63-80	adrenergic receptor, beta 1	Mus musculus	187-197
12606629-5	2003	Saturation binding of [(125)I]iodocyanopindolol to beta-AR subtypes revealed the presence of a high-affinity site (K(d1) = 96.4 +/- 8.7 pM; B(max1) = 12.5 +/- 0.6 fmol/mg protein) and a low-affinity site (K(d2) = 1.96 +/- 1.7 nM; B(max2) = 58.7 +/- 4.3 fmol/mg protein).	Iodocyanopindolol	30-47	adrenoceptor beta 2	Homo sapiens	51-58
10578240-8	1999	[125I]-Iodocyanopindolol binding to 5-HT1B sites in hippocampus was also not changed.	Iodocyanopindolol	7-24	5-hydroxytryptamine receptor 1B	Rattus norvegicus	36-42
12531948-6	2003	Beta(2) adrenoreceptor expression was assessed monthly using a ligand binding assay with [(125)I]iodocyanopindolol.	Iodocyanopindolol	97-114	adrenoceptor beta 2	Homo sapiens	0-22
9296350-5	1997	Expression of Gs alpha was strongly correlated to the appearance of GTP shifts in the competitive binding of epinephrine with [125I]iodocyanopindolol to the beta-adrenergic receptors and epinephrine-stimulated adenylyl cyclase activity.	Iodocyanopindolol	132-149	GNAS complex locus	Homo sapiens	14-22
10557026-3	1999	RESULTS: In CHO (Chinese hamster ovary) cells transfected with beta3-adrenoceptor cDNA, antibody labelling was found to be proportional to receptor density measured by the binding of the radiolabelled beta-adrenoceptor antagonist, [125I]-iodocyanopindolol.	Iodocyanopindolol	238-255	adrenoceptor beta 3	Homo sapiens	63-81
9630356-4	1998	In DDT cell membranes DCITC and HCITC inhibited (-)[125I]-iodocyanopindolol (CYP) binding to the beta-adrenoceptor with IC50 values of 1.1 and 18 nM, respectively.	Iodocyanopindolol	58-75	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	77-80
10435008-4	1999	METHODS: Cardiac beta-AR density was measured by [125I]-iodocyanopindolol binding to ventricular membranes.	Iodocyanopindolol	56-73	adrenergic receptor, beta 1	Mus musculus	17-24
9655586-7	1998	In ligand binding studies, anti-H24T antibodies at a concentration of 50 nM, increased the affinity (KD) of the radiolabeled antagonist [125I]iodocyanopindolol for the bovine beta2-AR from 31.7 pM to 25.3 pM (P < .05) without changing the receptor number.	Iodocyanopindolol	142-159	adrenoceptor beta 2	Bos taurus	175-183
8917438-6	1996	By using [125I]iodocyanopindolol to label all beta-adrenoceptors and ICI 118,551 to discriminate between the binding to beta 2- and beta 1-adrenoceptors we have demonstrated that the beta 2-adrenoceptor binding activity increases over control values in F28 mouse tissues that accumulate transgenic mRNA.	Iodocyanopindolol	15-32	adrenergic receptor, beta 2	Mus musculus	183-202
8630591-7	1996	In [125I]iodocyanopindolol-labeled bronchial membranes, formoterol and salmeterol induced high-affinity states of the beta 2-receptor (pKh 9.6 +/- 0.4 and 10.4 +/- 0.7, respectively), the former inducing a higher percentage (57 +/- 6 versus 28 +/- 4, p < 0.05).	Iodocyanopindolol	9-26	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	118-124
8878428-4	1996	Radioligand binding using [125I]iodocyanopindolol revealed a 32+/-7% reduction in beta-ARs in lung tissues from IL-1beta-treated rats, without any significant changes in beta2-AR mRNA level measured by Northern blot analysis.	Iodocyanopindolol	32-49	interleukin 1 beta	Rattus norvegicus	112-120
8930693-12	1996	In saturation homogenate binding studies of 5-HT1B sites using [125I]iodocyanopindolol 1 month after i.p.	Iodocyanopindolol	69-86	5-hydroxytryptamine receptor 1B	Rattus norvegicus	44-50
8646418-2	1996	Pindolol, cyanopindolol (CYP) and iodocyanopindolol (IodoCYP) have been reported to act either as antagonists, agonists or partial agonists at the beta 3-adrenoceptor in different preparations.	Iodocyanopindolol	34-51	adrenoceptor beta 3	Rattus norvegicus	147-166
8586585-5	1995	Beta 2-Adrenoceptor density (Bmax) was measured in these membrane preparations by saturating them with the radioligand [125I]iodocyanopindolol.	Iodocyanopindolol	125-142	adrenoceptor beta 2	Bos taurus	0-19
8646418-2	1996	Pindolol, cyanopindolol (CYP) and iodocyanopindolol (IodoCYP) have been reported to act either as antagonists, agonists or partial agonists at the beta 3-adrenoceptor in different preparations.	Iodocyanopindolol	53-60	adrenoceptor beta 3	Rattus norvegicus	147-166
8302276-4	1994	Similar to the cloned rodent 5-HT1B receptors, it had high affinity for the beta-adrenergic ligand [125I]iodocyanopindolol, because of the presence of an asparagine instead of a threonine residue in the seventh transmembrane region.	Iodocyanopindolol	105-122	5-hydroxytryptamine receptor 1B	Homo sapiens	29-35
7984276-7	1994	All mutant receptors bound [125I]iodocyanopindolol with high affinity, KD values ranging between 0.04 nM (mutant 5-HT1D alpha) and 0.57 nM (mutant 5-HT1E), whereas the wild-type receptors failed to show any specific binding with this radioligand in the same concentration range used for the mutant receptors.	Iodocyanopindolol	33-50	5-hydroxytryptamine receptor 1D	Homo sapiens	113-125
7984276-7	1994	All mutant receptors bound [125I]iodocyanopindolol with high affinity, KD values ranging between 0.04 nM (mutant 5-HT1D alpha) and 0.57 nM (mutant 5-HT1E), whereas the wild-type receptors failed to show any specific binding with this radioligand in the same concentration range used for the mutant receptors.	Iodocyanopindolol	33-50	5-hydroxytryptamine receptor 1E	Homo sapiens	147-153
7977723-2	1994	We report here that membrane preparations of female rat thymic tissue contain iodocyanopindolol binding sites that exhibit pharmacological properties typical of a beta-AR.	Iodocyanopindolol	78-95	adrenoceptor beta 2	Homo sapiens	163-170
7945736-2	1994	We studied the regional responses of [125I]iodocyanopindolol ([125I]ICYP)-labeled central 5-HT1B sites to chronic treatment with 5-HT agonists and antagonists at a dose of 10 mg/kg/d IP for 30 consecutive days in the rat.	Iodocyanopindolol	43-60	5-hydroxytryptamine receptor 1B	Rattus norvegicus	90-96
8361548-2	1993	The distribution of [125I]GTI binding sites was largely comparable to that of [125I]iodocyanopindolol ([125I] ICYP) which labels 5-HT1B binding sites (in the presence of 8-OH-DPAT (8-hydroxy-[2N-dipropylamino]tetralin) and isoprenaline, to prevent binding to 5-HT1A and beta-adrenoceptor binding sites), although a detailed analysis revealed differences.	Iodocyanopindolol	84-101	5-hydroxytryptamine receptor 1B	Rattus norvegicus	129-135
8217161-5	1993	Positive clones displayed dose-dependent uPA activity in response to isoproterenol, specifically bound the beta 2AR-agonist iodocyanopindolol and expressed beta 2AR-mRNA.	Iodocyanopindolol	124-141	plasminogen activator, urokinase	Sus scrofa	41-44
8217161-5	1993	Positive clones displayed dose-dependent uPA activity in response to isoproterenol, specifically bound the beta 2AR-agonist iodocyanopindolol and expressed beta 2AR-mRNA.	Iodocyanopindolol	124-141	adrenergic receptor, beta 2	Mus musculus	107-115
1695899-9	1990	125I-Labeled iodocyanopindolol bound transfectant membranes with an affinity of KD = 24 pm; the beta 1-AR-selective antagonist ICI 89,406 displaced iodocyanopindolol binding with a Ki approximately 140 times lower than that for the beta 2-AR-selective antagonist ICI 118,551.	Iodocyanopindolol	148-165	adrenoceptor beta 1	Rattus norvegicus	96-105
1352549-1	1992	In membrane preparations derived from primary cultures of chick myocardial cells, beta adrenergic receptors modeled for a single low-affinity site for both betaxolol (beta-1-selective) and ICI 118551 (beta-2-selective) displacement of [125I]iodocyanopindolol (ICYP), indicating that the chick beta receptor is pharmacologically distinct from both mammalian beta-1 and beta-2 adrenergic receptors with respect to these antagonists.	Iodocyanopindolol	241-258	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	201-207
1315641-4	1992	beta 2-Adrenergic receptors of these cells were covalently labeled with the lipophilic photoactivatable antagonist [125I]iodocyanopindolol diazarine, and specific radioligand binding sites were localized at the ultrastructural level of resolution with quantitative electron microscopic autoradiography.	Iodocyanopindolol	121-138	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	0-6
1548463-5	1992	The rank order of their binding affinities with this new radioligand showed a high degree of correlation with their affinities at the 5-HT1B receptor determined with [3H]5-HT or [125I]iodocyanopindolol.	Iodocyanopindolol	184-201	5-hydroxytryptamine receptor 1B	Rattus norvegicus	134-140
1328244-2	1992	At 48 h post-infection, a high level expression of an epitope-tagged beta 2-AR (10-25 pmol/mg protein) was detected by [125I]iodocyanopindolol ([125I]CYP) binding assays.	Iodocyanopindolol	125-142	adrenoceptor beta 2	Homo sapiens	69-78
1656540-1	1991	The density of [125I]iodo-cyanopindolol binding to beta-1 and beta-2 adrenergic receptors was studied in post mortem basal ganglia samples of Huntington"s chorea and Parkinson"s disease patients using autoradiography.	Iodocyanopindolol	21-39	BCL2 related protein A1	Homo sapiens	51-57
1839497-5	1991	[3H]Ketanserin binding to 5-HT2 receptors in the cortex, (-)[125I]-iodo-cyanopindolol [( 125I]CYP) binding to 5-HT1b receptors in the striatum and hypothalamus, and [3H] 8-OH-DPAT binding in the cortex were not affected by chronic ethanol administration.	Iodocyanopindolol	67-85	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	94-97
1839497-5	1991	[3H]Ketanserin binding to 5-HT2 receptors in the cortex, (-)[125I]-iodo-cyanopindolol [( 125I]CYP) binding to 5-HT1b receptors in the striatum and hypothalamus, and [3H] 8-OH-DPAT binding in the cortex were not affected by chronic ethanol administration.	Iodocyanopindolol	67-85	5-hydroxytryptamine receptor 1B	Rattus norvegicus	110-116
2545582-7	1989	The binding of 3H-QNB (quinuclidinyl benzilate) on mACh-R, 125I-CYP (iodocyanopindolol) on beta-AdR and 3H-imipramine on imipramine binding sites decreased by 60, 20 and 70% in the presence of 1 microM BF, respectively, while the addition of 1 microM BF inhibited MAO activity by about 50%.	Iodocyanopindolol	69-86	monoamine oxidase A	Rattus norvegicus	264-267
2512511-0	1989	G protein dependent alterations in [125I]iodocyanopindolol and +/- cyanopindolol binding at 5-HT1B binding sites in rat brain membranes.	Iodocyanopindolol	41-58	5-hydroxytryptamine receptor 1B	Rattus norvegicus	92-98
2512511-1	1989	Several manipulations that affect G protein/receptor coupling also alter the binding of [125I]iodocyanopindolol ([125I]ICYP) and [corrected] +/- cyanopindolol (+/- CYP) to rat brain 5-HT1B binding sites in radioligand binding assays.	Iodocyanopindolol	94-111	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	120-123
2512511-1	1989	Several manipulations that affect G protein/receptor coupling also alter the binding of [125I]iodocyanopindolol ([125I]ICYP) and [corrected] +/- cyanopindolol (+/- CYP) to rat brain 5-HT1B binding sites in radioligand binding assays.	Iodocyanopindolol	94-111	5-hydroxytryptamine receptor 1B	Rattus norvegicus	182-188
2532143-3	1989	Binding to the higher affinity site could be displaced by drugs in an order corresponding most closely with the 5-HT1B subtype, and high affinity [125I]iodo-cyanopindolol binding was also found.	Iodocyanopindolol	152-170	5-hydroxytryptamine receptor 1B	Rattus norvegicus	112-118
2836172-4	1988	Binding of the 125I-labeled beta-adrenergic ligand iodocyanopindolol ([125I]iodo-CYP) to GC was evaluated and was found to be saturable with time and ligand concentration, and of high affinity (Kd = 29 +/- 8 pM; maximum binding = 0.55 +/- 0.02 fmol/10(6) cells).	Iodocyanopindolol	51-68	peptidylprolyl isomerase G	Homo sapiens	81-84
3027484-5	1987	High affinity [125I]-iodocyanopindolol (CYP) binding to beta adrenergic receptors can also be demonstrated in DDT1 cells but not in L-cells.	Iodocyanopindolol	21-38	peptidylprolyl isomerase G	Homo sapiens	40-43
6090853-1	1984	A saturable, stereospecific high affinity beta 2 adrenergic receptor was demonstrated on intact human peripheral blood lymphocytes using the ligand [125I]-iodocyanopindolol ([125I]ICYP).	Iodocyanopindolol	155-172	adrenoceptor beta 2	Homo sapiens	42-68
2945992-4	1986	5-HT1A, 5-HT1B and 5-HT1C recognition sites were labelled with [3H]8-OH-DPAT([3H]8-hydroxy-2-(di-n-propylamino)-tetralin) in pig cortex membranes, [125I]CYP([125I]iodocyanopindolol) in rat cortex and [3H]mesulergine in pig choroid plexus membranes, respectively.	Iodocyanopindolol	162-180	5-hydroxytryptamine receptor 1A	Rattus norvegicus	0-6
2945992-4	1986	5-HT1A, 5-HT1B and 5-HT1C recognition sites were labelled with [3H]8-OH-DPAT([3H]8-hydroxy-2-(di-n-propylamino)-tetralin) in pig cortex membranes, [125I]CYP([125I]iodocyanopindolol) in rat cortex and [3H]mesulergine in pig choroid plexus membranes, respectively.	Iodocyanopindolol	162-180	5-hydroxytryptamine receptor 2C	Rattus norvegicus	19-25
2997551-1	1985	To investigate the mechanism underlying age-dependent changes in beta-adrenoceptor function we have determined beta 2-adrenoceptor density (by (+/-)-125iodocyanopindolol (ICYP) binding) and beta 2-responsiveness (cyclic AMP responses to isoprenaline stimulation) in lymphocytes derived from 20 neonates, 54 young adults (19-30 years) and 15 old subjects (60-86 years).	Iodocyanopindolol	171-175	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	111-117
3010694-1	1986	Beta 2-adrenergic receptors comprise 40% of the total beta-receptor population in failing human right ventricles, as deduced from computer modeling of iodine-125 iodocyanopindolol-ICI 118,551 competition curves.	Iodocyanopindolol	162-179	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	0-6
6206325-1	1984	In 41 normotensive volunteers (diastolic pressure, less than 90 mm Hg) the beta 2-adrenoceptor density in lymphocytes was determined by (+/-)-125 iodocyanopindolol (ICYP) binding and compared with that in nine patients with borderline hypertension (diastolic pressure, 90-95 mm Hg) and 45 patients with established essential hypertension (diastolic pressure, greater than 95 mm Hg).	Iodocyanopindolol	146-163	adrenoceptor beta 2	Homo sapiens	75-94